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Abstract
Retinitis pigmentosa (RP) is a group of inherited retinal degenerations that lead to progressive vision loss.
Over 200 mutations in 60 different genes have been shown to cause RP. Given the diversity of genes and
mutations that cause RP, corrective gene therapy approaches currently in development may prove both time-
consuming and cost-prohibitive for treatment of all forms of RP. An alternative approach is to find common
biological pathways that cause retinal degeneration in various forms of RP, and identify new molecular targets.
With this goal, we analyzed the retinal transcriptome of two non-allelic forms of RP in dogs, rcd1 and xlpra2,
at clinically relevant advanced stages of the two diseases. Both diseases showed very similar trends in changes
in gene expression compared to control normal dogs. Pathway analysis revealed upregulation of various
components of the innate immune system in both diseases, including inflammasome and complement
pathways. Our results show that the retinal transcriptome at advanced stages of RP is very similar to that of
other retinal degenerative diseases such as age-related macular degeneration and diabetic retinopathy. Thus,
drugs and therapeutics already in development for targeting these retinopathies may also prove useful for the
treatment of many forms of RP.
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Involvement of Innate Immune 
System in Late Stages of Inherited 
Photoreceptor Degeneration
Raghavi Sudharsan1, Daniel P. Beiting2, Gustavo D. Aguirre1 & William A. Beltran1
Retinitis pigmentosa (RP) is a group of inherited retinal degenerations that lead to progressive vision 
loss. Over 200 mutations in 60 different genes have been shown to cause RP. Given the diversity of 
genes and mutations that cause RP, corrective gene therapy approaches currently in development 
may prove both time-consuming and cost-prohibitive for treatment of all forms of RP. An alternative 
approach is to find common biological pathways that cause retinal degeneration in various forms of RP, 
and identify new molecular targets. With this goal, we analyzed the retinal transcriptome of two non-
allelic forms of RP in dogs, rcd1 and xlpra2, at clinically relevant advanced stages of the two diseases. 
Both diseases showed very similar trends in changes in gene expression compared to control normal 
dogs. Pathway analysis revealed upregulation of various components of the innate immune system in 
both diseases, including inflammasome and complement pathways. Our results show that the retinal 
transcriptome at advanced stages of RP is very similar to that of other retinal degenerative diseases 
such as age-related macular degeneration and diabetic retinopathy. Thus, drugs and therapeutics 
already in development for targeting these retinopathies may also prove useful for the treatment of 
many forms of RP.
Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal degenerations that leads to progressive 
vision loss due to death of rod and cone photoreceptor cells. With a prevalence of 1:4000, RP affects over 100,000 
individuals in the US and over a million worldwide1,2. Mutations in at least 60 different genes can cause RP 
(Retnet: https://sph.uth.edu/Retnet/; April 2017). Although there is considerable variation between the various 
forms of RP, rods are typically affected earlier in the course of the disease and cone impairment follows later. This 
temporal pattern typically causes night blindness in childhood/adolescence followed by progressive constriction 
of the visual field leading to retention of only central vision in adulthood. Complete blindness may occur later in 
life.
There is currently no cure for inherited retinal degenerations. Promising gene therapy approaches have been 
achieved in both small and large animal models, and some are now being translated towards clinical trials3. 
However, given the high cost to develop a marketable gene-specific therapy that by definition aims at replacing or 
correcting only one single defective gene, it is very unlikely that this approach will be used to target all the various 
forms of RP, as several fall within the group of ultra-orphan diseases. Identifying, instead, neuroprotective agents 
or cell death inhibitors that target cell signaling pathways common to various retinal degenerative diseases, may 
provide a “pan-RP” therapeutic option. While most proof of concept studies in animals are typically designed to 
demonstrate efficacy in preventing disease onset or halting retinal degeneration early in the disease, there is also a 
need for preclinical screening and assessment of such pharmacological compounds at later disease stages. Indeed, 
progressive retinal degeneration may go undetected earlier in life in asymptomatic RP patients until a significant 
number of photoreceptors are lost1. Therefore, identifying the survival and degenerative cell signaling pathways 
that are active in retinas at advanced stages of RP may provide relevant molecular targets for developing novel 
therapeutics.
In order to identify these common biological pathways, we have analyzed at advanced stages of disease (defined 
as more than 50% loss of photoreceptors) the retinal transcriptomic profile of two naturally-occurring, non-allelic 
forms of photoreceptor degeneration in dogs, namely, rcd1 and xlpra2. Rcd1 (rod cone dysplasia type 1) 
1Division of Experimental Retinal Therapies, Department of Clinical Sciences and Advanced Medicine, School of 
Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. 2Department of Pathobiology, 
School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. Correspondence and 
requests for materials should be addressed to W.A.B. (email: wbeltran@vet.upenn.edu)
Received: 26 May 2017
Accepted: 5 December 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCiEnTifiC REPORtS |  (2017) 7:17897  | DOI:10.1038/s41598-017-18236-7
is caused by a nonsense mutation in the beta subunit of rod-specific cGMP phosphodiesterase Pde6b4,5. Xlpra2 
(X-linked progressive retinal atrophy 2) is caused by a two-nucleotide deletion and frameshift in exon ORF15 of 
the retinitis pigmentosa GTPase regulator (RPGR) gene that is expressed in both rods and cones6. Mutations in 
both genes cause early onset retinal degeneration in people and in dogs7–9. In the canine models, an early burst of 
photoreceptor cell death is followed by a phase of protracted cell loss over the course of several months9,10. This 
kinetics of photoreceptor cell loss provide a reasonable experimental time-frame to examine the retinal altera-
tions that occur at advanced stages of disease.
Our study shows that the retinas of these two non-allelic canine models of RP shared similar changes in gene 
expression at late stage disease. Biological pathways related to the innate immune system and incriminated in 
other retinal degenerative diseases such as age-related macular degeneration (AMD) and diabetic retinopathy 
(DR), were also found to be activated in both models.
Results
Similar transcriptomic profile in rcd1 and xlpra2 retinas at late stage disease. To confirm the 
advanced stage of retinal degeneration in the three rcd1 (22 weeks of age) and three xlpra2 dogs (41 weeks of age) 
selected for transcriptomic analysis, their right eye was processed for histological evaluation (Supplementary 
Table S1). Quantification on H&E stained retinal cryosections of the thickness of the outer nuclear layer 
(ONL), which contains the photoreceptor somatas, showed a pan-retinal loss of photoreceptors in both dis-
eases (Fig. 1A1–2). The ONL thickness was reduced to less than 50% of normal in all four retinal quadrants 
(Fig. 1B1–4,C1–4,D1–4). The extent of photoreceptor cell loss was slightly higher for rcd1 compared to xlpra2 
consistent with the earlier onset and more severe progression of degeneration in this model10. Mean ONL thick-
ness (±S.D.) (measured as rows of nuclei) across all four quadrants was 2.6 (±0.6) for rcd1, 4.2 (±1.1) for xlpra2, 
and 9.9 (±1.1) for normal dogs. Accurate characterization of the structure of photoreceptor inner and outer 
segments could not be performed as these retinas were embedded without prior fixation.
In order to identify the molecular pathways active at this late stage of these two non-allelic retinal degenerative 
diseases, we performed RNA-seq analysis on the left neuroretinas from the three rcd1 and xlpra2 dogs, and com-
pared their transcriptomic profile to that of three adult normal dogs. The degree of similarity between the samples 
was visualized using a hierarchical clustering dendogram that showed distinct segregation of the group of normal 
dogs from the two sets of mutant animals (Fig. 2A). Each of the three rcd1 and xlpra2 animals further segregated 
from each other into distinct groups, indicating differences between the late stages of these two diseases. Likewise, 
a principal component analysis was performed and the first principal component (PC1) separated mutant dogs 
from the normal dogs, accounting for 42.5% of the variability in the dataset. The second principal component 
(PC2) separated the two diseases with 14.5% variability in the dataset (Fig. 2B). Thus, initial data assessment 
showed clear segregation between the three groups of animals, established distinction between normal versus 
mutant dogs, and indicated commonalities between the two mutant dogs which we explored further by identify-
ing the differentially expressed genes in the dataset.
A comparison between normal and rcd1 animals yielded 8,592 differentially expressed genes (DEGs; 
FDR ≤ 0.05). xlpra2 samples had 7,031 DEGs (FDR ≤ 0.05) (Supplementary Table S2). A heatmap of all DEGs 
showed that the levels of expression of a number of genes in the mutant animals was distinct from normal dogs, 
but that the pattern of retinal gene expression in the two diseases was very similar (Fig. 2C). Of the total DEGs 
identified, 3,102 genes in rcd1 and 1,747 genes in xlpra2 had a fold change value ≥2. Of the 1,747 DEGs identified 
in xlpra2 dogs, 1,503 (86%) were in common with rcd1 (Fig. 2D). In summary, our data indicated a high level of 
similarity in gene expression changes in the mutant retinas at late stages of photoreceptor degeneration.
Genes involved in innate immune responses are upregulated in late stages of retinal degeneration. 
In silico identification of biological pathways that are differentially regulated in late stage retinal degeneration was 
performed using the Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, www.ingenuity.com). Only DEGs 
with FDR ≤ 0.05 and absolute fold change ≥2 or more were used for functional analysis. In order to identify path-
ways involved in retinal degeneration, only canonical pathways known to be involved in cell signaling, neurode-
generation, and pro-/anti-apoptotic signaling were included in the analysis from the Ingenuity Knowledge Base, 
whereas most of the metabolic and cancer-related pathways were excluded. IPA identified 144 canonical path-
ways for rcd1 and 131 pathways for xlpra2 with a p-value of 0.05 or lower (−log(p-value) ≥1.3). Most of these 
IPA pathways have considerable overlap and redundant DEGs. Of these, 116 canonical pathways were common 
between the two diseases (Supplementary Table S3). Pathways that were identified in only one disease were also 
present for the other but did not meet the p-value cutoff. The only pathway unique to rcd1 was GABA receptor 
signaling. A complete analysis using all canonical pathways in the Ingenuity Canonical Pathway Knowledge Base 
is provided in Supplementary Table S4.
A number of biological pathways have been previously described by other groups to influence the course of 
degeneration in various retinal degenerative diseases such as RP, AMD and diabetic retinopathy (DR). These 
include the complement pathway11,12, inflammasome13,14, Toll-like receptor (TLR) pathway15,16, Tumor necrosis 
Factor (TNF)10,17 pathway, JAK-STAT pathway18, and number of pro-survival and cell death pathways19–22. The 
latter include caspase-dependent and caspase-independent apoptotic pathways as well as non-apoptotic cell death 
mechanisms involving histone deacetylases and poly-ADP-ribose-polymerases23–29. Many genes associated with 
these previously described pathways were found to be upregulated in the transcriptome of rcd1 and xlpra2 retinas 
at late stages of the diseases (Fig. 2D, Table 1, Supplementary Table S2). Curating the IPA data pointed towards 
the involvement of multiple innate immune responses and illustrated the complexity of the biology of retinal 
degeneration at late stage disease. To focus our efforts at identifying pathogenic mechanisms that influence retinal 
degeneration in rcd1 and xlpra2, and likely in other retinal degenerative diseases, only these previously described 
pathways were further validated at the transcript and protein levels in this study.
www.nature.com/scientificreports/
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QRT-PCR validation of genes involved in biological pathways identified in late stages of rcd1 
and xlpra2. To validate the RNA-seq results, quantitative real-time PCR (qRT-PCR) was performed on cDNA 
from the same retinal tissues to test for expression of a select number of genes representing these functional 
groups (Fig. 3A–F). Transcripts of several complement components involved in the classical pathway (C1QB, 
C1R, C1S), common to both the classical and alternative pathways (C3, C5, C7), and inhibitors and regulators 
of both pathways (CD55, CD59, CFI and CFH) were upregulated in advanced stages of rcd1 and xlpra2 reti-
nal degeneration. In addition, we analyzed the expression of two alternative complement pathway components, 
complement factor B (CFB) and complement factor D (CFD) that were not identified as differentially regulated 
by RNA-seq. Expression of CFB mRNA was significantly, albeit only slightly elevated (<2-fold) in xlpra2. The 
expression of CFD mRNA in the two mutants was not found to be significantly different from that of normal 
retina (Fig. 3A).
The expression of a number of TLR mRNAs such as TLR1, TLR2, TLR3, TLR7, TLR8, TLR9 and TLR10, as 
well as adaptor protein myeloid differentiation primary response 88 (Myd88) was found to be increased in both 
Figure 1. ONL count in normal and mutant retinas. (A1–2) Biaxial spidergraphs of outer nuclear layer 
thickness in the nasal-temporal and superior-inferior meridians for normal, rcd1 and xlpra2 retinas. H&E 
stained photomicrographs illustrating ONL thickness differences in the nasal, temporal, superior and inferior 
meridians of retina in a (B1–4) normal dog, (C1–4) rcd1 dog, and (D1–4) xlpra2 dog at 3000 ± 500 microns 
from the optic nerve head. RPE: Retinal Pigment Epithelium; ONL: Outer Nuclear Layer; INL: Inner Nuclear 
Layer; GCL: Ganglion Cell Layer; ONH: Optic Nerve Head.
www.nature.com/scientificreports/
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rcd1 and xlpra2 retinas by RNA-seq and validated by qRT-PCR (Fig. 3B). Upregulation of inflammasome com-
ponents NLRP3 and caspase-1, and pro-inflammatory cytokine IL-18 identified by RNA-seq analysis was also 
validated by qRT-PCR. Interleukin-1 beta (IL1B) and PYD-and-CARD-Domain-Containing (PYCARD) mRNA, 
two components of the inflammasome response that were not identified by RNA-seq as being differentially reg-
ulated, were found to be upregulated by qRT-PCR in the two diseases (Fig. 3C), although upregulation of IL1B 
was not significant in rcd1.
Figure 2. Gene level exploratory analysis and heat maps of differentially expressed genes in mutant retinas. 
(A) Hierarchical clustering of the Euclidean distances on log-transformed expression values in the RNA-seq 
dataset. (B) Principle component analysis on normalized gene expression values in RNA-seq data. (C) Heatmap 
of all differentially expressed genes with a p-value ≤ 0.05 in either one of the two mutants. Green indicates 
decrease and red indicates increase in gene expression. (D) Venn diagram indicating the number of distinct 
and overlapping differentially expressed genes in the two diseases. (E) Heatmap of a subset of differentially 
expressed genes grouped into pathways related to innate immune system or pro- and anti-apoptotic signaling 
and molecules.
www.nature.com/scientificreports/
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The gene expression values for all genes tested in the TNF pathway (TNFRSF1A, TNFRSF1B and FAS) and 
STAT-pathway (STAT1, STAT3, SOCS1, SOCS3) were found to be in agreement with that obtained by RNA-seq 
(Fig. 3D and E). With the exception of XIAP, which was found to not be downregulated by qRT-PCR analysis, 
the gene expression values for other anti-apoptotic genes (BCL2 and BIRC3) also agreed with that obtained by 
RNA-seq (Fig. 3F). Thus, results from qRT-PCR were consistent with RNA-seq expression results and validated 
further exploration of these functional pathways.
Ingenuity Canonical Pathways
−log(p-value)
Rcd1 Xlpra2
Complement System 5.03 ↑ 5.82 ↑
Inflammasome pathway 1.26 ↑ 1.75 ↑
JAK/Stat Signaling 2.18 ↑ 1.68 ↑
NF-κB Signaling 5.29 ↑ 5.36 ↑
Prolactin Signaling 2.53 ↑ 2.91 ↑
STAT3 Pathway 4.72 ↑ 2.54 ↑
TNFR1 Signaling 1.56 ↑ 0.795 ↑
TNFR2 Signaling 1.46 ↑ 1.72 ↑
Toll-like Receptor Signaling 4.61 ↑ 4.57 ↑
Table 1. List of canonical pathways identified by IPA that are common between the two diseases and described 
in this study. Pathways are listed alphabetically; all pathways in this list were predicted to be activated (↑) based 
on z-score obtained from IPA. The p-value threshold was set at 0.05 (−log(p-value) equivalent 1.3). A complete 
list of canonical pathways that were selected for IPA canonical pathway analysis for the two mutants is listed 
in Supplementary Table 3. A more comprehensive analysis with no exclusions is provided in Supplementary 
Table 4.
Figure 3. Validation of RNA-seq data by quantitative Real-Time PCR (qRT-PCR) in normal and mutant 
retinas. Results from qRT-PCR performed on a few select genes from: (A) Complement pathway; (B) Toll-like 
receptor family; (C) Inflammasome; (D) TNF superfamily; (E) STAT signaling; and (F) Pro-survival genes. The 
error bars represent the range of the fold change values. Significance is indicated by * for p-value ≤ 0.05 and ** 
for p-value ≤ 0.001. Dashed line indicates the 2-fold threshold for differentially expressed genes.
www.nature.com/scientificreports/
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Changes in expression of proteins of the innate immune system in degenerated retina. To 
investigate whether the transcriptomic changes translated to similar trends at the protein level, quantitative 
expression of some of the key pathway proteins was evaluated in the neuroretinal extracts from rcd1 and xlpra2 
retinas. Western blot analysis was performed on retinas from a limited number of dogs (3 normal, 3 rcd1 and 2 
xlpra2) at ages similar to that of retinas used for transcriptomic profiling. While the results showed a consistent 
trend in agreement with the transcriptomic data, statistical significance could not be established for any of the 
proteins tested due to small sample size (Fig. 4). The levels of complement component C3 in both diseases were 
increased when compared to normal. The mean levels of IL1β protein were also higher in the two disease states, 
although some individual variation was observed. For CASP1, NLRP3, BCL2 and BIRC3, the increase in protein 
levels were less pronounced but still reflected the trend observed by qRT-PCR. PYCARD did not show significant 
increase in the diseased state, while SOCS3 levels were decreased, in contrast with that observed for RNA levels. 
Total STAT3 was moderately increased in xlpra2 along with an increase in STAT3 phosphorylation.
To investigate whether these transcriptomic changes affected photoreceptor cells and/or other retinal cell 
populations, the expression and localization of a subset of proteins involved in innate immune response was 
examined by immunohistochemistry. Complement pathway component C3 was localized in the inner nuclear 
layer (INL; the layer containing the second order neurons, e.g. bipolar cells, horizontal cells) and photoreceptor 
inner segments of both rcd1 and xlpra2 retinas, as well as in the ONL of rcd1 retina (Fig. 5A1–3). Complement 
protein C9, a major component of the membrane attack complex (MAC), formed distinct puncta in the ONL of 
both mutant retinas, but not in the normal retina (5B1–3).
Increased staining for inflammasome pathway proteins NLRP3 (Nucleotide-binding Oligomerization 
domain-like (NOD-like) receptor pyrin domain containing 3) was observed in the ONL and the outer plex-
iform layer (OPL; the synaptic layer between photoreceptors and neurons in the INL) of the two mutant ret-
inas (Fig. 5C1–3). In addition, expression of caspase-1 (CASP1), the caspase responsible for pro-IL1β and 
pro-IL18 cleavage and activation during inflammation, was also increased in the ONL and INL of mutant retinas 
(Fig. 5D1–3). Increased expression of TNF superfamily receptor TNFRSF1B was seen in the OPL in the xlpra2 
retina (Fig. 5E1–3). Cell surface death receptor FAS showed increased expression in the rcd1 retina in distinct cell 
populations in the INL and also in ganglion cell layer (GCL) (Fig. 5F1–3).
The expression of NFκB subunit RELA (p65) was found to be slightly elevated in the ONL and INL of rcd1 ret-
ina (Fig. 5G1–3). Expression of STAT3 (signal transducer and activator of transcription 3) was found to be high in 
all three nuclear layers (ONL, INL and GCL) in the mutant animals, and particularly abundant in the ONL of rcd1 
retina (Fig. 5H1–3). Finally, slight increase in the immunostaining of anti-apoptotic protein BIRC3 (baculoviral 
IAP repeat containing 3) was observed in the ONL of mutant retinas, particularly in rcd1 (Fig. 5I1–3). Due to aut-
ofluorescence in the RPE, likely caused by accumulation of lipofuscin, this layer could not be evaluated for protein 
localization in the two diseases. In summary, we confirmed that the transcriptomic changes were frequently par-
alleled by similar trends at the protein level and changes in protein expression in various retinal layers. Although 
the two diseases primarily result in death of photoreceptors, significant alterations in other retinal layers occurs 
possibly as a response to ongoing photoreceptor cell death. The expression of several protein components of the 
innate immune system in the degenerating retina confirms that activation of innate immunity may play an impor-
tant role in photoreceptor death in late stage photoreceptor degeneration.
Discussion
In this study, we present evidence that a number of innate immune pathways and inflammation processes are 
activated at late stages of two forms of RP with different causative mutations. Inflammation has been shown to 
play a critical role in pathogenicity of many ocular and retinal diseases such as AMD, DR, uveitis and proliferative 
vitreoretinopathy. This study now provides evidence that innate immune responses may play an important role 
in various forms of RP as well.
Figure 4. Quantitation of protein levels in the mutant canine retinas in late stages of RP. Representative 
immunoblots and quantitation of protein levels in mutant (rcd1, n = 3; xlpra2, n = 2) retinas compared to 
normal retina (n = 3). Error bars represent standard deviation.
www.nature.com/scientificreports/
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In recent years, the role of innate immunity and inflammation in mediating cell death after tissue damage has 
taken prominence in the field of neurodegeneration. Besides its role in self/non-self-discrimination and defense 
against pathogens, it is now well established that one of the major roles for innate immunity is to sense tissue 
damage and activate sterile inflammation responses from immune cells. Non-immune cells also participate in 
sterile immunity through secretion of cytokines and inflammatory mediators, and activation of innate immune 
receptors30–32. While the purpose of an inflammatory response is to eliminate damaged tissues and promote 
healing, continuous stressors, such as those arising from tissue damage and cell death in inherited degenerative 
diseases, may lead to a hyperactive and sustained inflammatory response. This can further contribute to dis-
ease pathogenicity rather than leading to its resolution. The complement system33, pattern recognition receptors 
such as certain TLRs16,34, and NLRP313,35, as well as pro-inflammatory cytokines such as IL-1β, IL-18, IL-33 and 
TNF-α36,37 are all essential mediators of innate immune response and sterile inflammation.
The involvement of both classical and alternative complement pathways is well-established in many ocular and 
retinal diseases38. A number of studies have established a clear association between AMD and complement path-
ways12,39,40. Similarly, increase in components of both the alternative41,42 and the classical pathways43 is observed 
in DR. Evidence for alterations in the complement system is not limited to diseases that affect initially the RPE, 
but is also found in other retinopathies that first involve photoreceptor cells. A transcriptomic study in the rd10 
mouse, a model of RP caused by a spontaneous mutation in Pde6b gene, at a stage when rod photoreceptors have 
completely degenerated also revealed an increase in many classical and alternative complement pathway compo-
nents such as complement components C1Q, C1R, C3 and C444. Similar to these diseases, transcripts of several 
complement components were upregulated in advanced stages of rcd1 and xlpra2 retinal degeneration. We also 
found in these retinas a trend suggesting an increase in the protein levels of the pivotal component C3, the site of 
convergence of the three complement pathways. Although we were unable to confirm formation of the MAC due 
to lack of canine reactive anti-MAC antibodies (see Supplementary Table S6), staining with anti-C9 antibody, a 
major protein component of the MAC, showed accumulation of distinct protein aggregates only in the photore-
ceptor ONL of the diseased animals. This finding strongly suggests that loss of photoreceptors at late stage disease 
may be MAC-mediated. Thus, involvement of complement proteins in retinal degeneration in the two models of 
RP explored here parallels similar findings for other retinal diseases. Although the classical complement pathway 
Figure 5. Immunohistochemical localization of select pathway proteins in normal and mutant retina. (A1–3) 
Complement component C3; (B1–3) Complement component and component of the membrane attack 
complex (MAC) C9; (C1–3) Inflammasome component NLRP3; (D1–3) Apoptosis executor and IL1β activator 
protein Caspase-1 (CASP1); (E1–3) TNF superfamily receptor TNFRSF1B; (F1–3) Cell surface death receptor 
FAS; (G1–3) Transcription factor of NFκB family, RELA (p65); (H1–3) Transcription activator protein of STAT 
family, STAT3; (I1–3) Anti-apoptotic protein BIRC3. RPE: Retinal Pigment Epithelium; ONL: Outer Nuclear 
Layer; OPL: Outer Plexiform Layer; INL: Inner Nuclear Layer; GCL: Ganglion Cell Layer.
www.nature.com/scientificreports/
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appears to be the primary mediator of innate immunity in the mutant eyes, we cannot completely exclude the 
involvement of alternative complement pathway in the two diseases.
The TLRs are pattern recognition receptors that play an important role in the innate immune system by rec-
ognizing conserved microbial motifs called pathogen-associated molecular patterns (PAMPs), as well as many 
endogenous damage-associated molecular patterns (DAMPs), such as high-mobility group B1, heat shock pro-
teins, extracellular matrix components, beta amyloid, and self RNA and DNA45–47. Several members of the TLR 
family have been implicated in sterile immune responses and in the inflammatory component of several associ-
ated diseases, including neurodegeneration48,49. In addition to their expression on immune cells, TLR expression 
has been shown in non-immune cells, such as photoreceptors50 and RPE cells51. In the eye, TLRs have been 
implicated in retinal ischemia, glaucoma and DR16. The expression of a number of TLR mRNAs was found to 
be increased in both rcd1 and xlpra2 retinas. However, lack of canine-reactive anti-TLR antibodies precluded 
immunohistochemical determination of the retinal cell populations expressing these TLRs. TLR engagement 
leads to activation of transcription factors such as MAPK and NFκB (found to be expressed in the INL and ONL 
of the rcd1 retina) via the adaptor protein myeloid differentiation primary response 88 (Myd88). Activation of 
NFκB leads to transcription of inflammatory cytokines, including pro-IL1-β and the inflammasome component 
NLRP352.
This study also identified an upregulation of inflammasome related components NLRP3, PYCARD (ASC), 
caspase-1, pro-inflammatory cytokines IL-1β, IL-18, IL-33, and the IL-1 receptor (IL-1R) in rcd1 and xlpra2 
retinas. In addition, we confirmed increased expression of NLRP3 and caspase-1 proteins in various layers of 
the mutant retinas. NLRP3 inflammasome activation is a two-step process53; the priming signal involves TLR 
activation or TNF receptor activation that leads to transcription of NLRP3. A second activating signal leads 
to oligomerization of NLRP3, its assembly with PYCARD (ASC) and pro-caspase-1 to form a functional 
inflammasome, auto-catalytic activation of caspase-1 and subsequently, formation of mature secreted forms of 
pro-inflammatory cytokines IL-1β and IL-1854,55. Similar to our findings, these inflammation-related molecules 
are upregulated in other retinal degenerative diseases. In a recent publication, Appelbaum et al.56 have shown that 
expression of inflammasome components occurs even earlier in rcd1 and xlpra2, around the peak of cell death10 
observed in the two diseases. The NLRP3 inflammasome has also been recently implicated in photoreceptor cell 
death in the Rhodopsin P23H mouse model of RP57 and in the Pde6b mutant rd1 mouse model15. In addition, 
NLRP3 inflammasome is implicated in disease progression in AMD58–62 and DR63–65.
It is well established that the TNF pathway is a key mediator of inflammation in many ocular diseases includ-
ing diabetic retinopathy, uveitis, proliferative vitreoretinopathy, macular edema and wet AMD17,66. We previously 
showed that in the early stages of rcd1 and xlpra2 disease, TNF-superfamily members are upregulated and may 
thus contribute to the disease pathogenicity10. In the current study, continued upregulation of several of the 
TNF-superfamily genes, including the TNF receptors 1 A and 1B, and cell death receptor FAS, was observed at 
late stages of the two diseases; however, unlike at the earlier stages, levels of TNF-α were not significantly elevated 
in the late stage retina. This suggests that targeting TNF-α may be a valid therapeutic strategy but only earlier in 
the course of photoreceptor degeneration.
An initial acute burst of photoreceptor cell death followed by a protracted death of remaining photoreceptors 
that extends over several weeks or months has been reported in several rodent and canine models of RP9,10,29. 
While the deleterious effects of the mutations maybe directly responsible for the early loss of rods67,68, the second 
phase of slow cell loss may be the result of an interplay between photoreceptor survival pathways and chronic 
inflammatory processes. Increased expression of anti-apoptotic protein BIRC3 in the ONL and increase in 
BCL2 mRNA was observed in both rcd1 and xlpra2 retinas. On the other hand, neurotrophic factors such as 
CNTF, GDNF, BDNF, NGF and bFGF that are known to improve photoreceptor survival69, were not significantly 
increased. Noteworthy, however, was the very significant upregulation of the prolactin hormone mRNA, which 
has been shown to play a protective role in retinal degeneration70–72 (Supplementary Table S2). Our transcrip-
tomic data also revealed an increase in a number of non-apoptotic pathway genes that have been implicated in 
retinal degeneration, such as a number of poly-ADP-ribose-polymerases (PARP9, PARP14, PARP15) and histone 
deacetylases (HDAC7, HDAC10, HDAC11).
Availability of a low number of animals at advanced stages of disease, particularly of xlpra2 dogs, was a lim-
itation of this study. There was, however, some concordant trends in mRNA and protein level changes, in par-
ticular for components of the complement and inflammasome pathways. Even though the two diseases result 
primarily in a loss of photoreceptors, the inflammatory responses appear to involve other retinal cell populations 
as expression of several of the innate immune proteins occurred in the inner retina. The role of microglia and 
inflammatory cells such as macrophages has been described for several retinal degenerative models44,73–78. The 
contribution of neuronal cells as well as microglia to inflammation in late stages of RP will be the subject of future 
investigations. Although we expected to see some of the inflammation pathways to be active in RPE cells as well, 
increased autofluorescence presumably due to lipofuscin accumulation79 in the RPE cells in the late stages of the 
two diseases precluded further immunohistochemical evaluation of this layer.
In summary, our results indicate that more than one innate immune response pathway is activated in both dis-
eases at advanced stages of degeneration. This work, complements two other studies10,56 that assessed by qRT-PCR 
in early stages of rcd1 and xlpra2 diseases the expression of a limited number of pre-selected genes involved in 
inflammatory pathways. Taken together these results suggest that the transcriptomic profile of a retina under-
going photoreceptor loss evolves with the stage of degeneration. For example, while the inflammasome pathway 
appears to be activated throughout early to late disease56, increased expression of TNF-α was only found shortly 
after disease onset10. In addition, as this current study utilized RNA-seq technology, it provided a considerably 
more comprehensive analysis of the biological pathways involved in late stage retinal degeneration. As a result, we 
were able to identify upregulated genes (e.g. components of the complement pathway) not previously reported in 
these models of RP. Presence of multiple inflammation pathways in the two diseases is expected as these various 
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components of the inflammatory pathways do not work in isolation but stimulate and augment each other’s 
activation and function. Parallels have been shown in AMD where C1q, a complement protein known to be a 
component of AMD drussen, is known to activate NLRP3 function and stimulate IL-1β and IL-18 secretion80. 
Formation of MAC at sub-lethal levels also activates NLRP3 inflammasome81.
In conclusion, this is the first study comparing the retinal transcriptome of two non-allelic animal models 
of late stage RP. The results of this work, conducted in two naturally-occurring canine models, suggest that the 
involvement of the innate immune system may be a common response in late stage RP and, while localized to 
other retinal layers than the RPE, shows striking similarities with the profile of AMD and DR. A number of 
pharmacological therapeutics currently on the market or in development for these common retinopathies target 
inflammation molecules such as complement pathway proteins12 and IL-1β82 and thus opens the possibility for 
also testing similar strategies for the treatment of late stage RP.
Methods
Animals. Retinas from five female normal dogs (age: 24–26 weeks), six female rcd1 affected dogs (age: 22 
weeks) and five female xlpra2 affected dogs (age: 41 weeks) were used (Supplementary Table S1) for this study. 
Mutant animals were selected at an age where the ONL thickness in the retina had decreased to less than 50% of 
that of normal dogs. All dogs were housed under identical conditions (diet, ambient illumination with cyclic 12 
hrs ON-12 hrs OFF light) at the Retinal Disease Studies (RDS) facility at the University of Pennsylvania. The stud-
ies strictly adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania. Dogs 
were euthanized with an intravenous injection of sodium pentobarbital. After enucleation, the neuroretina was 
removed and stored at −80 °C until further experiments, or the posterior eyecup dissected into four quadrants 
and embedded in Optimal Cutting Temperature (OCT) medium without prior fixation.
RNA isolation. Neuroretinas from 3 normal, 3 rcd1, and 3 xlpra2 dogs were homogenized in TRIzol 
(Invitrogen, Thermo Fisher Scientific) using the BeadBug microtube homogenizer (Benchmark Scientific) and 
total RNA was extracted using the standard Trizol extraction protocol. RNA was treated with Turbo DNA-free 
kit (Thermo Fisher Scientific) to remove any genomic DNA contamination. RNA was quantified using the 
Nanodrop-1000 (ND-1000) spectrophotometer (Nanodrop Technologies, Thermo Scientific) and the quality of 
RNA was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies). All RNA samples had a RIN number 
>9 and were used for preparation of a cDNA library for RNA-seq.
cDNA library preparation, RNA-seq and analysis. A cDNA library from the 9 samples was prepared 
using Illumina Truseq mRNA library prep kit v2 and used for 100 bp single read sequencing on an Illumina 
Hiseq 2000 device. The resulting sequence data were recorded in FASTQ format (GEO accession GSE97638). 
Only high-quality reads were retained and any reads with a poor quality run of ≥5 were eliminated. Reads that 
aligned to a generic set of sequences containing ribosomal and known repeat sequences in humans were also 
removed before further analysis of the sequencing data. RNA-seq Unified Mapper (RUM)83 was used for aligning 
reads to known transcripts included in RefSeq, UCSC known genes and ENSEMBL transcripts, and to the dog 
genome. Unique alignments to RefSeq were extracted from the RUM output. Statistical and graphical analysis of 
RNA-seq data was carried out using R/Bioconductor. Differential gene expression analysis was performed using 
EdgeR package from R/Bioconductor84. The p-values were corrected for multiple testing using the Benjamini 
and Hochberg mode of the R function p.adjust to compute the false discovery rate. Heatmaps were generated 
using heatmaps.2 function of gplots package in R/Bioconductor. Differentially expressed genes (DEGs) with a 
p ≤ 0.05 and at least a 2-fold (±) difference in expression compared to normal were considered for further anal-
ysis. Annotation and pathway analysis on differentially expressed genes was performed using Ingenuity Pathway 
Analysis (Ingenuity® Systems, Spring Release 2017, www.ingenuity.com). Pathways with a −log(p-value) score 
of minimum 1.3 (Fisher’s exact test) and that were relevant to retinal degeneration were selected for further 
characterization.
qRT-PCR. Expression of select genes in each of the 9 RNA samples (3 per group) was further examined using 
qRT-PCR. Total RNA was reverse transcribed into cDNA using the High Capacity RNA to cDNA kit (Applied 
Biosystems, Thermo Fisher Scientific). Gene-specific PCR primer pairs were designed using the free PrimerQuest 
Tool from Integrated DNA Technologies. Primers used for qRT-PCR have been listed in Supplementary Table S5. 
qRT-PCR was performed either on a 7500 Fast Real-Time PCR system (96-well format) or ViiA 7 Real-Time PCR 
System (348-well format) (Applied Biosystems, Thermo Fisher Scientific). Each 20 ul reaction contained 5 ng 
of cDNA, 10 ul of SYBR Green PCR Mastermix (Life Technologies, Thermo Fisher Scientific) and 250 nM each 
forward and reverse primers. Each sample was analyzed in triplicates. Comparative deltaCt method was used for 
relative comparison of gene expression levels using GAPDH as an endogenous control for normalization. Fold 
change was calculated as 2−(ΔΔCt) and statistical significance was calculated by an unpaired homoscedastic t-test 
using a two-tailed distribution.
Retinal morphology and morphometry. H&E stained retinal cryosections (12 µm-thick) extending from 
the optic nerve head (ONH) to the ora serrata along the 4 meridians (superior, inferior, nasal and temporal) were 
examined under bright field microscopy (Axioplan, Carl Zeiss Meditec GmbH, Oberkochen, Germany) with a 
40X objective. Number of ONL nuclei were counted every 1,000 microns and the ONL thickness was plotted on 
biaxial (superior/inferior and nasal/temporal) spidergraphs.
Western blot analysis. Neuroretinal extracts were prepared from 3 normal, 3 rcd1 and 2 xlpra2 retinas in a 
buffer containing 0.23 M sucrose, 2 mM EDTA, 5 mM Tris HCl, pH 7.4, 1% Tx100 and a protease and phosphatase 
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inhibitor cocktail (Halt, Thermo Scientific, Waltham, MA). The retinas were first homogenized by vortexing with 
1.5 mm zirconium beads (Benchmark Scientific Inc., Sayreville, NJ) and then sonicated. The samples were then 
centrifuged and total protein concentration in the supernatant measured by BCA assay. 50 µgs of total protein 
from each sample was resolved on an 8–16% Tris Glycine gel (Invitrogen, Carlsbad, CA), transferred to a nitro-
cellulose membrane (iBLOT, Invitrogen) and immunoblotted using antibodies listed in Supplementary Table 6. 
After incubation with infrared dye-tagged secondary antibodies, protein bands were visualized on a digital imag-
ing system (Odyssey Fc, Licor, Lincoln, NE). Quantification was performed using the Licor Image Studio v4.0 
software using β-actin bands for normalization. Statistical significance was calculated for rcd1 samples only by 
unpaired homoscedastic t-test using a two-tailed distribution.
Immunohistochemistry. Expression and localization of select proteins was analyzed by immunohisto-
chemistry using a panel of antibodies (listed in Supplementary Table S6) on 12 µm-thick retinal sections from 
the superior part of retina. The sections were incubated with primary antibodies at 4 °C overnight after a block-
ing step with buffer containing 5% BSA and 4.5% fish gelatin in PBS at room temperature. Antigen antibody 
complexes were visualized with Alexa-fluor labeled secondary antibodies (Invitrogen, Thermo Fisher Scientific). 
DAPI stain was used to label the nuclei. After mounting in Gelvatol Mounting medium (containing polyvinyl 
alcohol and glycerol), slides were examined with an epifluorescence microscope (Axioplan, Carl Zeiss Meditec), 
images were digitally captured using Spot 4.0 camera and prepared for display using Adobe Photoshop and 
Illustrator programs.
Data Availability. Transcriptomic data (RNA-seq) generated for this study are available in the GEO reposi-
tory (accession number GSE97638). Ingenuity pathway analysis data are provided either as Supplementary infor-
mation file or available from the corresponding author on reasonable request.
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